Neurotrope Financial Statements (NTRP)
|
|
|
|
Report date
|
|
|
08.03.2019 |
13.03.2020 |
31.12.2020 |
31.12.2021 |
31.12.2022 |
|
30.09.2023 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.807 |
1.65 |
0.630 |
|
0.523 |
|
Operating Income, bln rub |
|
|
-11.1 |
-15.5 |
-5.70 |
-8.48 |
-8.75 |
|
-5.93 |
|
EBITDA, bln rub |
? |
|
-11.0 |
-15.1 |
-5.08 |
-7.28 |
-8.55 |
|
-5.76 |
|
Net profit, bln rub |
? |
|
-11.0 |
-15.1 |
-5.20 |
-7.38 |
-8.69 |
|
-5.88 |
|
|
OCF, bln rub |
? |
|
-7.70 |
-11.9 |
-4.81 |
-6.30 |
-8.21 |
|
-4.41 |
|
CAPEX, bln rub |
? |
|
0.003 |
0.005 |
0.299 |
0.360 |
0.389 |
|
0.275 |
|
FCF, bln rub |
? |
|
-7.70 |
-11.9 |
-5.11 |
-6.66 |
-8.60 |
|
-4.69 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
11.1 |
15.5 |
5.76 |
9.57 |
8.95 |
|
6.14 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.592 |
0.560 |
0.350 |
|
0.313 |
|
R&D, bln rub |
|
|
4.89 |
4.54 |
0.351 |
0.891 |
0.653 |
|
0.443 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.014 |
0.011 |
0.007 |
|
0.012 |
|
|
Assets, bln rub |
|
|
29.5 |
17.9 |
5.70 |
13.8 |
5.70 |
|
2.84 |
|
Net Assets, bln rub |
? |
|
26.5 |
17.4 |
5.16 |
12.9 |
5.07 |
|
1.97 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
28.9 |
17.4 |
3.70 |
11.4 |
2.85 |
|
0.556 |
|
Net debt, bln rub |
|
|
-28.9 |
-17.4 |
-3.70 |
-11.4 |
-2.85 |
|
-0.56 |
|
|
Ordinary share price, rub |
|
|
30.0 |
19.6 |
67.6 |
36.8 |
8.00 |
|
0.945 |
|
Number of ordinary shares, mln |
|
|
8.05 |
13.0 |
0.191 |
0.491 |
0.525 |
|
0.560 |
|
|
Market cap, bln rub |
|
|
242 |
255 |
13 |
18 |
4 |
|
1 |
|
EV, bln rub |
? |
|
213 |
238 |
9 |
7 |
1 |
|
0 |
|
Book value, bln rub |
|
|
27 |
17 |
4 |
12 |
4 |
|
1 |
|
|
EPS, rub |
? |
|
-1.37 |
-1.16 |
-27.2 |
-15.0 |
-16.6 |
|
-10.5 |
|
FCF/share, rub |
|
|
-0.96 |
-0.92 |
-26.7 |
-13.5 |
-16.4 |
|
-8.37 |
|
BV/share, rub |
|
|
3.29 |
1.34 |
23.0 |
24.3 |
7.52 |
|
1.30 |
|
|
EBITDA margin, % |
? |
|
|
|
-629.0% |
-440.7% |
-1 357% |
|
-1 102% |
|
Net margin, % |
? |
|
|
|
-644.0% |
-447.1% |
-1 379% |
|
-1 124% |
|
FCF yield, % |
? |
|
-3.19% |
-4.66% |
-39.5% |
-36.8% |
-204.8% |
|
-885.4% |
|
ROE, % |
? |
|
-41.6% |
-86.9% |
-100.7% |
-57.4% |
-171.3% |
|
-297.7% |
|
ROA, % |
? |
|
-37.4% |
-84.6% |
-91.2% |
-53.4% |
-152.4% |
|
-207.1% |
|
|
P/E |
? |
|
-21.9 |
-16.9 |
-2.49 |
-2.45 |
-0.48 |
|
-0.09 |
|
P/FCF |
|
|
-31.4 |
-21.5 |
-2.53 |
-2.72 |
-0.49 |
|
-0.11 |
|
P/S |
? |
|
|
|
16.0 |
10.9 |
6.66 |
|
1.01 |
|
P/BV |
? |
|
9.11 |
14.6 |
2.93 |
1.52 |
1.06 |
|
0.73 |
|
EV/EBITDA |
? |
|
-19.3 |
-15.7 |
-1.82 |
-0.91 |
-0.16 |
|
0.00 |
|
Debt/EBITDA |
|
|
2.62 |
1.15 |
0.73 |
1.57 |
0.33 |
|
0.10 |
|
|
R&D/CAPEX, % |
|
|
153 345% |
87 091% |
117.6% |
247.5% |
167.9% |
|
161.3% |
|
|
CAPEX/Revenue, % |
|
|
|
|
37.0% |
21.8% |
61.7% |
|
52.5% |
|
| Neurotrope shareholders |
